Clinical Trials Browser

Active not recruiting × Interventional × sotorasib × Clear all

NCT06333951 2026-05-28

Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT05638295 2026-05-13

Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial)

Phase 2 Active not recruiting

Neoplasm Metastasis

NCT04303780 2026-04-30

Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200).

Phase 3 Active not recruiting

345 enrolled 11 charts

KRAS p, G12c Mutated /Advanced Metastatic NSCLC

NCT06497556 2026-04-20

Krascendo 1

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03600883 2026-03-16

A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)

Phase 1/2 Active not recruiting

713 enrolled 1 FDA

Other solid neoplasm

KRAS p.G12C Mutant Advanced Solid Tumors

NCT05074810 2026-01-12

RAMP203

Phase 1/2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT04625647 2025-12-05

Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

Phase 2 Active not recruiting

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04185883 2025-10-22

Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

Phase 1 Active not recruiting

Other solid neoplasmSarcoma

Advanced Solid Tumors